polymorphisms with breast cancer-specific and all-cause mortality after a breast cancer diagnosis remains, however, largely unexplored. We assessed the association of genetic variants in VDR (rs731236, rs1989969, rs2228570, 11568820) with breast cancer survival in a sample of 498 breast cancer patients with a mean age at diagnosis of 61 years from Saarland, Germany, who were followed for up to 5 years with respect to total and breast cancer-specific mortality (56 and 48 events, respectively). Adjusted hazard ratios with 95% confidence intervals (CI) were estimated by Cox regression models. We found that breast cancer patients homozygous for the rare allele of rs731236 (15% of the women in our cohort) had a tendency toward an increased risk for breast cancer-specific mortality. The hazard ratio (95% CI) adjusted for age and breast cancer stage was 2.8 (1.1-7.2) for breast cancer-specific mortality and 2.1 (0.9-4.9) for total mortality. Additional adjustment for family history of breast cancer, radical mastectomy, and body mass index changed only marginally the estimates. No association was found for rs1989969, rs2228570, and rs11568820. Our analysis suggests that VDR polymorphism rs731236 might be associated with breast cancer-specific mortality and if our findings are confirmed in future and bigger studies rs731236 might deserve consideration as a prognostic factor in clinical care of breast cancer patients.
INTRODUCTION
The hypothesis that vitamin D might have a positive effect in reducing cancer risk first emerged from ecological studies showing an association between cancer mortality and latitude, with lower mortality rates at lower latitudes (1) . A possible explanation for this difference was thought to be the different exposure to ultraviolet radiation and its effect on the production of vitamin D. Laboratory studies corroborated this hypothesis by showing that 1,25-dihydroxyvitamin D [1,25(OH)2D] had an antiproliferative effect and was involved in the differentiation and apoptosis of cancer cells (2) . It is speculated that the anticancerogenous effects of vitamin D are mediated through the vitamin D receptor (VDR) (3).
In particular, 1,25-dihydroxyvitamin D, the active metabolite of vitamin D, binds to VDR and stimulates cell differentiation and immunological function (4) . The VDR gene, located on the chromosome 12q13.1 (5) , is expressed in most cancer cells (2) and presents several single nucleotide polymorphisms (SNP), which seem to be of relevance for breast cancer (6, 7) . A possible mechanism explaining the involvement of genetic variants in VDR on breast cancer might be the observed association between serum concentrations of 1,25(OH)2D and VDR polymorphism. In particular, Morrison and colleagues found that serum concentrations of 1,25(OH)2D, which is thought to be involved in the differentiation and growth of breast cancer cells (2) , varied in the different genotypes of VDR polymorphism rs1544410 (8).
However, very scant work investigated the association of VDR polymorphisms with breast cancer survival and no study analyzed the association with breast cancer-specific mortality. A German cohort study analyzing the association of VDR expression and survival among 82 breast cancer patients aged 54-95 years observed high VDR expression to be associated with better progression-free survival and overall survival compared to low VDR expression (9) . The rs731236 polymorphism was assessed in 721 breast cancer patients below 65 years of age in the UK. A non-significant 55% increase in total mortality was observed Swedish breast cancer patients below 37 years of age found a trend towards a higher survival among estrogen receptor-positive tamoxifen-treated patients homozygous for the rare allele of rs731236 (11) .
Given these very few and partly conflicting results, we aimed to assess whether genetic variations in VDR, including rs731236, are associated with breast cancer-specific and all-cause mortality in a cohort of breast cancer patients from population-based studies in Germany.
MATERIALS AND METHODS

Study population
This analysis is based on two cancer cohort studies conducted in Saarland, Germany, the ESTHER II study and the VERDI study. Patients with primary breast cancer were recruited statewide in both studies in Saarland, a federal state of Germany, at their first diagnosis of cancer disease. The state of Saarland was chosen, inter alia, as highly efficient and reliable long-term follow-up of cancer patients is possible through the Saarland Cancer Registry (12) .
In the ESTHER II study more than 2,000 patients aged 50-74 years and diagnosed with various forms of cancer were recruited between January 2001 and December 2003 (13); in the VERDI study 908 patients aged ≤ 80 years with a first diagnosis of breast, colorectal, or gastric cancer were recruited between October 1996 and February 1998 (14). 
SNP genotyping
Details of SNP genotyping have been described previously (16). Briefly, DNA was extracted from blood samples collected at baseline and genotyped with Sequenom's MassARRAY® system (Sequenom, San Diego, USA) in collaboration with the Women' s clinic of the University of Heidelberg. Of 299 duplicate samples, 289 (97%) were completely (100%) concordant on all loci and were used for the present analysis.
According to pertinent literature (6, 17), we analysed rs731236 (Taq1), rs2228570 (Fok1), rs11568820 (Cdx2), and rs1989969 (VDR-5132). For technical reasons we could not analyse rs1544410 (Bsm1) and rs7975232 (Apa1).
Statistical analysis
Descriptive statistics were used to show the baseline characteristics of the participants by study. Deviation from the Hardy-Weinberg equilibrium (HWE) was tested using chi square statistics. Cox regression models were performed in order to estimate hazard ratios for allcause and breast cancer-specific mortality, with partial or full adjustment for the following 
RESULTS
Main characteristics of the study population are presented in Table 1 . Our cohort of 498 breast cancer patients had a mean age of 61 years. During 5-year follow-up 56 women died. For 48 women a malignant neoplasm of the breast was indicated as the underlying cause of death (ICD-10, C50). Genotype distributions were very similar in the ESTHER II and VERDI subcohorts and no significant deviation from HWE was observed. In three of the analyzed SNPs of the VDR gene the heterozygous genotype was the most common genotype (prevalence ranging from 46% to 50%). The large majority (84%) of patients were diagnosed at stages I or II according to the staging system of the UICC. Only a small minority (4%) had distant metastasis (stage IV).
In the Cox proportional hazards model there was no indication for violation of the proportional hazards assumption. None of the time dependent covariates included in the model was significant. The results of the Cox proportional hazards model are shown in Table   2 . A significant association between the rs731236 rare homozygous genotype and breast cancer-specific and all-cause mortality was found. Homozygous carriers of the rare allele had almost a threefold probability of death from breast cancer compared to homozygous Stratification of results by oestrogen and progesterone receptor status yielded similarly elevated hazard ratios for all subgroups, albeit with wide confidence intervals due to the low number of stratum cases (data not shown).
DISCUSSION
In this cohort of 498 breast cancer patients, we observed both in partially and fully adjusted models a strong association between rs731236 and breast cancer-specific mortality. These findings point to a possible relevance of rs731236 for breast cancer prognosis.
To our knowledge, no previous study has assessed the association of rs731236 with breast cancer-specific mortality. Increased total mortality has previously been reported for homozygous carriers of the rare allele from a study among breast cancer patients below 65 years of age, but the increase in risk was less pronounced and not statistically significant (10) . Unfortunately, we could not test this hypothesis because it was not possible to obtain serum concentrations of 1,25(OH)2D.
Another important limitation of the study is that, given the limited sample size and number of events, confidence intervals around the estimated hazard ratios are rather wide.
Despite its limitations, our analysis points to a potential prognostic value of rs731236 among breast cancer patients. If our results are confirmed in further studies with larger sample size and further differentiation in patient subgroups is possible, characterization of breast cancer patients by rs731236 genotype may become a useful supplement for risk stratification that might be of potential relevance for treatment decisions. cebp.aacrjournals.org
